NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Free Report) shares were up 17.7% on Thursday . The stock traded as high as $4.00 and last traded at $4.12. Approximately 230,989 shares changed hands during trading, a decline of 88% from the average daily volume of 1,986,156 shares. The stock had previously closed at $3.50.
NovaBay Pharmaceuticals Trading Down 1.3%
The firm’s 50 day simple moving average is $1.34 and its 200-day simple moving average is $1.21. The stock has a market capitalization of $435.49 million, a price-to-earnings ratio of -0.35 and a beta of 0.57.
NovaBay Pharmaceuticals Announces Dividend
The firm also recently declared a dividend, which was paid on Monday, September 29th. Investors of record on Wednesday, October 1st were given a dividend of $0.80 per share. This represents a yield of 3,791.0%. The ex-dividend date of this dividend was Tuesday, September 30th.
Institutional Investors Weigh In On NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
Featured Stories
- Five stocks we like better than NovaBay Pharmaceuticals
- What Are Some of the Best Large-Cap Stocks to Buy?
- Dollar General’s Turnaround Could Send the Stock Higher in 2026
- What Is WallStreetBets and What Stocks Are They Targeting?
- Don’t Bet Against AppLovin: The Case Against the Shorts
- How to Evaluate a Stock Before Buying
- Micron’s Q1 Results Say “AI Bubble Is Far From Bursting”
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
